The longevity industry is having a moment. Consumer interest is surging, investment capital is flowing in, and new clinics, testing panels and interventions are launching at a pace the sector has never seen before.
On the surface, this looks like progress. Look closer, and a different picture emerges: the science supporting many of these products and services has not kept up with the enthusiasm surrounding them.
That gap between hype and evidence is now one of the defining tensions in preventive health. And a growing number of operators inside the industry are saying so publicly, because the credibility of the entire category depends on it.
The Credibility Gap Is Widening
“Demand is clearly outrunning credibility in longevity,” says Niko Hems, Head of Strategy and Growth at YEARS, a German preventive health company. “Consumer interest, capital and the number of clinics, tests and interventions are growing faster than the evidence base and clinical standards behind them.”
The numbers back him up. Biological-age testing has moved from research labs to consumer apps in a matter of years. Supplement stacks marketed for cellular health are sold without long-term human outcome data. Broad screening panels promise early detection of conditions that may never develop. Each of these occupies a different point on the evidence spectrum, yet all are marketed with similar confidence.
The result is a market where consumers struggle to tell the difference between medicine and marketing. That confusion is not just a commercial problem. It risks eroding trust in the legitimate science that does exist, including the preventive medicine practices with strong clinical backing.
Three Categories, One Shelf
Part of the problem is structural. “Validated preventive medicine, promising but early science, and commercially attractive claims are often presented side by side without enough distinction between what improves outcomes, what merely changes a biomarker, and what has barely been tested in humans,” Hems explains.
That side-by-side presentation creates a credibility gap around several areas in particular: biological-age testing, broad screening, supplement stacks and many so-called anti-ageing interventions. In each case, adoption has moved ahead of prospective outcome data, meaning people are buying based on promise rather than proof.
The distinction matters more than most marketing suggests. A biomarker that shifts after an intervention is not the same as a health outcome that improves. A study on mice is not a study on humans. An early-stage finding is not a validated clinical standard. When the industry blurs these lines, it borrows credibility from real science to sell products that have not earned it.
Setting a Higher Bar
The companies that will define the next phase of longevity are the ones willing to hold themselves to a stricter standard. “The industry will earn trust by setting a higher bar: transparent evidence grading, physician oversight, clear communication of uncertainty, fewer surrogate endpoints, more longitudinal data, and a willingness to say when an intervention is interesting but not yet proven,” says Niko Hems, Head of Strategy and Growth at YEARS.
At YEARS, that principle is not a marketing position. It is how the company operates. Jürgen Mehrtens, co-founder and CEO of the Berlin-Charlottenburg-based clinic, build YEARS after more than a decade as an entrepreneur at the intersection of technology, health and growth, with one clear vision: precision preventive medicine should no longer be a privilege for the few, but systematically accessible for anyone serious about their long-term health.
The idea came from a simple observation. The German healthcare system is excellent at treating acute disease, but structurally too late. Most chronic conditions that shorten lives today can be detected years before they manifest, if you measure the right markers and bring the right specialists together. YEARS closes that gap with an evidence-based approach: 87 to 230+ biomarkers, physician-led diagnostics under one roof, an individual prevention plan, and long-term care.
“Prevention is the most important investment a person can make in their future. YEARS makes it measurable, precise, and accessible,” says Mehrtens.
This positioning is not just ethical. It is commercially rational. As the longevity market matures, consumers and corporate buyers are becoming more discerning. Companies that can demonstrate evidence-based practice will increasingly stand apart from those that cannot.
Conclusion
The longevity boom is not slowing down, and neither should the scrutiny that comes with it. The gap between what the industry promises and what the science supports is real, and it will not close on its own. Operators like Niko Hems are making the case that credibility is not a constraint on growth but the foundation of it. The companies that embrace transparency, physician oversight and honest communication about uncertainty will be the ones still standing when the hype cycle moves on. In a field built on the promise of longer, healthier lives, trust is the most valuable asset of all.